Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Virology

• Publication date

  2001-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.75.24.12198-12208.2001PMID 11711611PMCID PMC116117
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The antiviral activity of antibodies in vitro and in vivo

  2004cited by this paper
• Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro

  2001influential reference
• Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41

  2001influential reference
• gp120: Biologic aspects of structural features.

  2001cited by this paper
• Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design

  2001cited by this paper
• Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies.

  2001cited by this paper
• Processing, Stability, and Receptor Binding Properties of Oligomeric Envelope Glycoprotein from a Primary HIV-1 Isolate*

  2000cited by this paper
• Generation and Structural Analysis of Soluble Oligomeric gp140 Envelope Proteins Derived from Neutralization-Resistant and Neutralization-Susceptible Primary HIV Type 1 Isolates

  2000cited by this paper
• Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection

  2000cited by this paper
• Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

  2000cited by this paper
• The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

  1999cited by this paper
• Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

  1999cited by this paper
• Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys

  1999cited by this paper
• Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies

  1998cited by this paper
• The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

  1998cited by this paper
• Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity

  1998cited by this paper
• Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins

  1998cited by this paper
• Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.

  1997cited by this paper
• Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".

  1997cited by this paper
• Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12

  1997cited by this paper
• Synergistic Neutralization of a Chimeric SIV/HIV Type 1 Virus with Combinations of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies or Hyperimmune Globulins

  1997cited by this paper
• Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1

  1997cited by this paper
• Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein

  1997cited by this paper
• Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype

  1997cited by this paper
• A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

  1996cited by this paper
• In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope

  1996influential reference
• Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation

  1996cited by this paper
• Neutralization of HIV-1 by antibody.

  1996influential reference
• The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate

  1996cited by this paper
• Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein

  1996cited by this paper
• Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5

  1996cited by this paper
• Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

  1996cited by this paper
• Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site

  1996influential reference
• Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site

  1995cited by this paper
• Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

  1995cited by this paper
• Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.

  1995cited by this paper
• Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.

  1995cited by this paper
• Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG

  1995cited by this paper
• Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

  1994cited by this paper
• Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1

  1994cited by this paper
• Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

  1994cited by this paper
• Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities

  1994cited by this paper
• Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies.

  1993influential reference
• A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

  1993cited by this paper
• Synergistic Inhibition of HIV-1 Envelope-Mediated Cell Fusion by CD4-Based Molecules in Combination with Antibodies to gp120 or gp41

  1993cited by this paper
• Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gpl20

  1992cited by this paper
• Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene

  1992cited by this paper
• Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein.

  1992cited by this paper
• An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1

  1992cited by this paper
• Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120

  1992cited by this paper
• Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.

  1992cited by this paper
• Synergism and antagonism in chemotherapy

  1991cited by this paper
• A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

  1991cited by this paper
• COMBO: A New Approach to the Analysis of Drug Combinations in Vitro a

  1990cited by this paper
• Synergistic Drug Combinations in AIDS Therapy

  1990cited by this paper
• Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

  1990cited by this paper
• Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

  1987cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984influential reference
• T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III.

  1984cited by this paper

• Antibodies and cryptographic hash functions: quantifying the specificity paradox

  2025cites this paper
• The TZM-bl Reporter Cell Line Expresses Kynureninase That Can Neutralize 2F5-like Antibodies in the HIV-1 Neutralization Assay

  2022cites this paper
• Avidity in antibody effector functions and biotherapeutic drug design

  2022cites this paper
• A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

  2021cites this paper
• CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection

  2021cites this paper
• Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever.

  2021cites this paper
• A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

  2021cites this paper
• The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19

  2021cites this paper
• Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates

  2020cites this paper
• Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments

  2020cites this paper
• A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction

  2020cites this paper
• A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

  2020cites this paper
• Shaping Polyclonal Responses via Antigen-Mediated Antibody Interference

  2020cites this paper
• Chronic Viral Infection Promotes Efficient Germinal Center B Cell Responses

  2020cites this paper
• HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design: A Review of 20 Years of Research

  2019cites this paper
• The preparation and therapeutic roles of scFv-Fc antibody against Staphylococcus aureus infection to control bovine mastitis

  2019cites this paper
• HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay

  2018cites this paper
• Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry

  2018cites this paper
• Functional assessment on non-neutralizing binding antibodies in the blood and genital tracts of women with breakthrough HIV infection from the CAPRISA 004 1% tenofovir gel trial.

  2017cites this paper
• Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA

  2017cites this paper
• Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy

  2017cites this paper
• Engineering antibody-like inhibitors to prevent and treat HIV-1 infection

  2017cites this paper
• From DEPARTMENT OF BIOSCIENCES AND NUTRITION Karolinska Institutet, Stockholm, Sweden UNDERSTANDING STRUCTURAL FEATURES OF BIOMOLECULAR INTERACTIONS: FROM CLASSICAL SIMULATIONS TO AB INITIO CALCULATIONS

  2017cites this paper
• Anti-Staphylococcus aureus single-chain variable region fragments provide protection against mastitis in mice

  2016cites this paper
• Engineering broadly neutralizing antibodies for HIV prevention and therapy.

  2016cites this paper
• neutralizing antibodies for HIV prevention and therapy ☆ O F

  2016cites this paper
• Commentary: Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking

  2016cites this paper
• Evaluating the Synergistic Neutralizing Effect of Anti-Botulinum Oligoclonal Antibody Preparations

  2014cites this paper
• An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine

  2014cites this paper
• Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes

  2014cites this paper
• The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.

  2014cites this paper
• Estimating the Probability of Polyreactive Antibodies 4E10 and 2F5 Disabling a gp41 Trimer after T Cell-HIV Adhesion

  2014cites this paper
• Simultaneously Targeting Tissue Transglutaminase and Kidney Type Glutaminase Sensitizes Cancer Cells to Acid Toxicity and Offers New Opportunities for Therapeutic Intervention

  2014cites this paper
• HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities

  2014cites this paper
• Targeting the CD4- and Coreceptor-Binding Sites of the HIV-1 Envelope Glycoprotein

  2014cites this paper
• the Native Antigen 4E10 Recognizes N-Terminal Sequences on The HIV-Neutralizing Monoclonal Antibody

  2013cites this paper
• Monoclonal antibodies for prophylactic and therapeutic use against viral infections

  2013cites this paper
• Identification of a new epitope for HIV‐neutralizing antibodies in the gp41 membrane proximal external region by an Env‐tailored phage display library

  2013cites this paper
• eview onoclonal antibodies for prophylactic and therapeutic use against viral

  2013cites this paper
• Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS

  2013cites this paper
• Monoclonal antibodies for prophylactic and therapeutic use against viral infections

  2013cites this paper
• Closing the door to human immunodeficiency virus

  2013cites this paper
• Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses

  2013cites this paper
• Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases

  2013cites this paper
• Multiantibody Strategies for HIV

  2013cites this paper
• Maize seeds as a production and delivery platform for HIV microbicides

  2013cites this paper
• Topological Analysis of HIV-1 Glycoproteins Expressed In Situ on Virus Surfaces Reveals Tighter Packing but Greater Conformational Flexibility than for Soluble gp120

  2013cites this paper
• Adsorption and folding dynamics of MPER of HIV‐1 gp41 in the presence of dpc micelle

  2013cites this paper
• Neutralizing Epitopes in the Membrane-Proximal External Region of HIV-1 gp41 Are Influenced by the Transmembrane Domain and the Plasma Membrane

  2012cites this paper
• Neutralization Interfering Antibodies: A “Novel” Example of Humoral Immune Dysfunction Facilitating Viral Escape?

  2012cites this paper
• Antibody Guided Exploration of V3 Exposure on Subtype C HIV

  2012cites this paper
• The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells.

  2012cites this paper
• A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design.

  2012cites this paper
• Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

  2012cites this paper
• Basic research in HIV vaccinology is hampered by reductionist thinking

  2012cites this paper
• An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

  2012cites this paper
• Basic research in HIV vaccinology is hampered by reductionist thinking

  2012cites this paper
• UCLA1, a Synthetic Derivative of a gp120 RNA Aptamer, Inhibits Entry of Human Immunodeficiency Virus Type 1 Subtype C

  2012cites this paper
• Intrahost evolution of HIV-1 phenotypes

  2012cites this paper
• HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes

  2012cites this paper
• The Neutralizing Anti-HIV Antibody 2G12

  2012cites this paper
• Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice.

  2012cites this paper
• Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine

  2011cites this paper
• Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

  2011cites this paper
• Cross-Clade HIV-1 Neutralizing Antibodies Induced with V3-Scaffold Protein Immunogens following Priming with gp120 DNA

  2011cites this paper
• Synthesis and biological evaluation of 2',4'- and 3',4'-bridged nucleoside analogues.

  2011cites this paper
• Diagnosis and Prognosis of Severe Dengue

  2011influential citation
• Constrained peptide models from phage display libraries highlighting the cognate epitope-specific potential of the anti-HIV-1 mAb 2F5.

  2011cites this paper
• Identification of potential epitopes for the design of HIV-1 vaccine in Kenya

  2011cites this paper
• Limitations to the structure‐based design of HIV‐1 vaccine immunogens

  2011influential citation
• Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site

  2011cites this paper
• Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

  2011cites this paper
• Functional Stability of Unliganded Envelope Glycoprotein Spikes among Isolates of Human Immunodeficiency Virus Type 1 (HIV-1)

  2011cites this paper
• The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis

  2011cites this paper
• Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16

  2010cites this paper
• Similar T-Cell Immune Responses Induced by Group M Consensus Env Immunogens with Wild-Type or Minimum Consensus Variable Regions

  2010cites this paper
• Macaques Vaccinated with Simian Immunodeficiency Virus SIVmac239Δnef Delay Acquisition and Control Replication after Repeated Low-Dose Heterologous SIV Challenge

  2010cites this paper
• Interfacial properties and structure stability of the gp41 tryptophan-rich peptide from HIV-1.

  2010cites this paper
• Macaque Long-Term Nonprogressors Resist Superinfection with Multiple CD8+ T Cell Escape Variants of Simian Immunodeficiency Virus

  2010cites this paper
• Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region

  2010cites this paper
• Inhibition of HIV‐1 Entry: Multiple Keys to Close the Door

  2010cites this paper
• Dimeric 2G12 as a Potent Protection against HIV-1

  2010cites this paper
• The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

  2010cites this paper
• Neutralization of Clostridium difficile toxin A using antibody combinations

  2010cites this paper
• Synthetic Peptide Vaccines and the Search for Neutralization B Cell Epitopes

  2009cites this paper
• UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins

  2009cites this paper
• Functional, Non-Clonal IgMa-Restricted B Cell Receptor Interactions with the HIV-1 Envelope gp41 Membrane Proximal External Region

  2009cites this paper
• Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes.

  2009cites this paper
• HIV-1/SIV Neutralizing Antibody Gene Delivery: A Novel Vaccination Approach

  2009cites this paper
• Combination Therapy Using Chimeric Monoclonal Antibodies Protects Mice from Lethal H5N1 Infection and Prevents Formation of Escape Mutants

  2009cites this paper
• B lymphocytes. broadly neutralizing anti-HIV antibody after in vitro maturation to human Engineering human hematopoietic stem/progenitor cells to produce a

  2009cites this paper
• HIV-Envelope–Dependent Cell-Cell Fusion: Quantitative Studies

  2009cites this paper
• The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent.

  2008cites this paper
• The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design

  2008cites this paper
• Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding.

  2008cites this paper
• The Human Immunodeficiency Virus Type 1 Envelope Spike of Primary Viruses Can Suppress Antibody Access to Variable Regions

  2008influential citation
• Neutralizing antibodies decrease the envelope fluidity of HIV-1.

  2008cites this paper
• Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.

  2008cites this paper
• Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.

  2007cites this paper
• Microbicide drug candidates to prevent HIV infection.

  2007cites this paper